# Rammeaftale om køb af Breyanzi (lisocabtagene maraleucel)

- **Source:** TED · `159884-2026`
- **Buyer:** Amgros I/S
- **Published:** 2026-03-09
- **Deadline:** —
- **Estimated value:** 154,000,000 DKK
- **CPV codes:** 33600000
- **Place-of-performance NUTS:** DK011, DNK
- **Buyer-address NUTS:** —
- **Notice type:** can-standard / 29

## Procedure details

Source lists may span several lots; list positions do not establish relationships.

### Procedure Types

- neg-wo-call

### Award Criterion Descriptions

- Direkte tildeling (ingen tildelingskriterier anvendt)

## Description

Formålet med rammeaftalen er at kunne forsyne sygehusapotekerne hos Amgros' interessenter med lægemidlet Breyanzi (lisocabtagene maraleucel). Region Hovedstadens sygehusapotek foretager endvidere indkøb med henblik på videresalg Grønland og Færøerne.

## Award result

- **Published notice total:** 154,000,000 DKK
- **Contract concluded:** 2025-08-15
- **Winner:** Bristol-Myers Squibb Denmark. Filial Af Bristol-Myers Squibb AB. Sverige (CVR 20315407) · value 154,000,000 DKK
Published values may cover multiple lots, options and frameworks; they are not supplier revenue. Unlinked notice summaries do not assign each value or expiry to each winner.

## Original notice

https://ted.europa.eu/da/notice/-/detail/159884-2026